东北制药集团股份有限公司 2024 年半年报财务报表 东北制药集团股份有限公司 2024 年半年报财务报表 1、合并资产负债表 编制单位：东北制药集团股份有限公司 2024 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 4,892,107,187.47 | 5,651,183,181.94 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | | | | 衍生金融资产 | | | | 应收票据 | 531,049,967.79 | 583,583,587.31 | | 应收账款 | 2,270,426,311.74 | 1,813,637,017.43 | | 应收款项融资 | | | | 预付款项 | 51,244,978.86 | 150,056,969.66 | | 应收保费 | | | | 应收分保账款 | | | | 应收分保合同准备金 | | | | 其他应收款 | 238,693,407.81 | 191,253,188.85 | | 其中：应收利息 | ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥4,168,516,475.19, a decrease of 7.50% compared to ¥4,506,385,834.60 in the same period last year[11]. - Net profit attributable to shareholders was ¥156,809,500.46, representing an increase of 16.25% from ¥134,886,215.06 year-on-year[11]. - The net profit after deducting non-recurring gains and losses was ¥104,566,182.46, up 27.58% from ¥81,958,837.83 in the previous year[11]. - The net cash flow from operating activities increased by 33.65% to ¥354,842,185.55, compared to ¥265,506,202.28 in the same period last year[11]. - Basic and diluted earnings per share were both ¥0.110, reflecting a growth of 17.02% from ¥0.094[11]. - Total assets at the end of the reporting period were ¥14,669,703,511.51, a decrease of 3.95% from ¥15,273,653,642.13 at the end of the previous year[11]. - Net assets attributable to shareholders increased by 0.81% to ¥5,028,573,650.43 from ¥4,988,269,769.70 at the end of the previous year[11]. - The company's total revenue for the first half of 2024 reached CNY 1,903,784,451.19, representing a 10.35% increase compared to the same period last year[42]. - The pharmaceutical manufacturing segment generated ¥2,195,653,726.98, accounting for 52.67% of total operating revenue, down 18.92% from the previous year[41]. - The company achieved a net increase in cash and cash equivalents of ¥373,911,552.46, a significant increase of 688.29% compared to a decrease of ¥63,559,148.46 in the previous year[40]. Research and Development - The company has established a national-level enterprise technology center and an innovative drug incubation base, enhancing its R&D capabilities[15]. - The company has made significant progress in R&D, with key products like L-Carnitine and Vitamin C obtaining CEP registration, and several new drug registrations completed[31]. - The company is actively developing new products and technologies, with ongoing clinical trials for several key drugs aimed at addressing various health conditions[26]. - The company plans to continue increasing R&D investment, focusing on expanding therapeutic areas and extending the industrial chain[56]. - Research and development expenses decreased by 19.85% to ¥45,355,698.92 from ¥56,591,347.65[40]. Product Development and Market Position - Northeast Pharmaceutical Group is a significant drug production and export base in China, with over 400 types of chemical raw materials and formulations, exporting to more than 100 countries and regions[15]. - The company has developed a variety of products, including vitamin C series, which utilizes a unique two-step fermentation method and is exported to over 60 countries[16]. - The company is a major global producer of fosfomycin sodium, with its product "Fumeixin" recognized as a famous trademark in China[17]. - The company has launched several new products, including acetyl L-carnitine, which is the first approved pharmaceutical raw material in China, and has a strong presence in the reproductive health sector[17]. - The company is a leading producer of piracetam, primarily used for cognitive disorders, and has a significant market share in the neuropharmaceutical sector[17]. - The company has introduced a range of anti-AIDS products, including zidovudine, which was the first drug approved by the FDA for HIV treatment[18]. - The company has a diverse product line in the digestive system category, including probiotics and other formulations for gastrointestinal health[18]. - The company is expanding its product offerings in the health sector, with a focus on vitamin C and other health supplements, creating a diversified product system[19]. Sales and Marketing Strategy - The company has established a comprehensive sales network covering Liaoning and Jilin provinces, with strategic partnerships with influential domestic and international companies[23]. - The company is focusing on expanding its e-commerce presence through platforms like JD.com, Tmall, and Pinduoduo, enhancing its online sales capabilities[25]. - The company has a diverse sales model, including self-operated and agent/distribution channels, catering to different customer needs[22]. Environmental Compliance and Sustainability - Northeast Pharmaceutical Group reported strict compliance with environmental protection laws, including the Environmental Protection Law and the Air Pollution Prevention Law, among others[70]. - The company has obtained pollution discharge permits for its Zhangshi and Chemical Park facilities, valid until April 2029 and July 2029, respectively[73]. - The company has established a comprehensive environmental management system to monitor and report on pollution control measures[73]. - The company has invested over 72.33 million yuan in environmental governance and protection in the first half of 2024, and paid environmental protection tax of 79,256.64 yuan[86]. - The company has implemented various air pollution control technologies, including SCR denitrification and bag dust collection systems[82]. Financial Management and Shareholder Information - The company does not plan to distribute cash dividends or issue bonus shares for the half-year period[61]. - The total number of shares increased from 1,347,873,265 to 1,424,383,265 due to the implementation of the 2022 restricted stock incentive plan[63]. - The company has maintained a consistent guarantee amount of 260,000,000 CNY across multiple transactions[102]. - The total approved guarantee amount for subsidiaries during the reporting period is CNY 510,000,000, with actual guarantees amounting to CNY 172,070,000[105]. - The company has not engaged in any related party transactions during the reporting period[94]. Risk Management - The company faced risks from intensified market competition and price pressures in the pharmaceutical industry, prompting strategic adjustments to ensure stable production and cost management[53][54]. - The company faced increasing environmental pressures due to stricter regulations, leading to higher production costs and squeezed profit margins[55]. Corporate Governance - The annual shareholders' meeting had a participation rate of 55.99% on April 19, 2024, while the first extraordinary shareholders' meeting of 2024 had a participation rate of 55.56% on May 14, 2024[59]. - The company has not reported any significant changes in its financial dealings with related parties[97]. - The company has no significant litigation or arbitration matters during the reporting period[92].

公司法定代表人：郭建民 主管会计工作的公司负责人: 宋家纶 公司会计机构负责人：周雅娜 东北制药集团股份有限公司2024年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | | 占用方与上市公司的关联 | 上市公司核算 | 2024年期初占用 | 2024年半年度占用累计 | 2024年半年度占用 | 2024年半年度偿 | 2024年半年度期 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 关系 | 的会计科目 | 资金余额 | 发生金额（不含利息） | 资金的利息(如有) | 还累计发生金额 | 末占用资金余额 占用形成原因 | | 占用性质 | | 控股股东、实际控制人 | | | | | | | | - | | | | 及其附属企业 | | | | | | | | - | | | | 小计 | | | | | | | | | | | | 前控股股东、实际控制 | | | | | | | | | | | | 人及其附属企业 | | | | | | | ...

证券代码：000597 证券简称：东北制药 公告编号：2024-049 二、董事会会议审议情况 会议审议并以记名投票表决方式通过以下议案： 议案一：关于公司《2024 年半年度报告》及摘要的议案 具体内容详见巨潮资讯网披露的《东北制药集团股份有限公司 2024 年半年 度报告》及《东北制药集团股份有限公司 2024 年半年度报告摘要》（公告编号： 2024-051）。 东北制药集团股份有限公司 第九届董事会第三十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 1.东北制药集团股份有限公司（以下简称"公司"）第九届董事会第三十次 会议于 2024 年 8 月 17 日发出会议通知，于 2024 年 8 月 27 日以通讯表决的方式 召开。 2.会议应参加董事 11 人，实际参加董事 11 人。 3.本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件和《东北制药集团股份有限公司章程》的规定，会议形成的决议合法 有效。 表决结果：同意 11 票，反对 0 票，弃权 0 票。 议案二：关于新增关联方及新 ...

证券代码：000597 证券简称：东北制药 公告编号：2024-053 东北制药集团股份有限公司 关于召开公司 2024 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、召开会议的基本情况 1.股东大会届次：本次股东大会为公司 2024 年第二次临时股东大会。 2.股东大会的召集人：公司董事会。2024 年 8 月 27 日，东北制药集团股份 有限公司（以下简称"公司"）第九届董事会第三十次会议，以同意 11 票，反对 0 票，弃权 0 票，审议通过了《关于召开公司 2024 年第二次临时股东大会的议案》。 3.会议召开的合法、合规性：公司第九届董事会第三十次会议决定召开本次 股东大会。本次股东大会会议召开符合有关法律、行政法规、部门规章、规范性 文件、深圳证券交易所业务规则和《东北制药集团股份有限公司章程》等规定。 4.会议召开的日期、时间： （1）现场会议召开时间：2024 年 9 月 12 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2024 年 9 月 12 日 9:15—9:25 ...

证券代码：000597 证券简称：东北制药 公告编号：2024-050 二、监事会会议审议情况 会议审议并以记名投票表决方式通过以下议案： 议案一：关于公司《2024 年半年度报告》及摘要的议案 具体内容详见巨潮资讯网披露的《东北制药集团股份有限公司 2024 年半年 度报告》及《东北制药集团股份有限公司 2024 年半年度报告摘要》（公告编号： 2024-051）。 东北制药集团股份有限公司 第九届监事会第二十三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 1.东北制药集团股份有限公司（以下简称"公司"）第九届监事会第二十三 次会议于 2024 年 8 月 17 日发出会议通知，于 2024 年 8 月 27 日以通讯表决的方 式召开。 2.会议应参加监事 3 人，实际参加监事 3 人。 3.本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件和《东北制药集团股份有限公司章程》的规定，会议形成的决议合法 有效。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 议案二：关于新增关联方及新增 ...

证券代码：000597 证券简称：东北制药 公告编号：2024-052 东北制药集团股份有限公司 关于新增关联方及新增 2024 年度日常关联交易预计的公告 公司于 2024 年 3 月 28 日召开第九届董事会第二十五次会议和第九届监事会 第二十次会议，审议通过了《关于调整 2024 年度日常关联交易预计的议案》。 为适应市场需求，更好开展各项业务，根据公司日常经营的实际需要，公司需对 2024 年度日常关联交易预计金额进行调整。经业务部门重新测算，公司及子公 司 2024 年度同关联方发生各类日常关联交易预计总额调整为 24,410 万元。具体 内容详见公司于巨潮资讯网披露的《东北制药集团股份有限公司关于调整 2024 年度日常关联交易预计的公告》（公告编号：2024-018）。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 （二）审议程序 公司于 2024 年 8 月 27 日召开第九届董事会第三十次会议，以同意 5 票，反 对 0 票，弃权 0 票，回避 6 票，审议通过了《关于新增关联方及新增 2024 年度 日常关联交易预计的议案》，关联董事郭建 ...

东北制药集团股份有限公司第九届董事会 独立董事 2024 年第三次专门会议审议意见 根据《深圳证券交易所股票上市规则》《上市公司独立董事规则》和《东北 制药集团股份有限公司章程》《东北制药集团股份有限公司独立董事工作细则》 等有关规定，作为东北制药集团股份有限公司（以下简称"公司"）的独立董事， 我们对第九届董事会独立董事 2024 年第三次专门会议的相关议案进行了认真审 议，现就相关议案发表审议意见如下： 一、关于新增关联方及新增 2024 年度日常关联交易预计的议案 公司及子公司与相关关联方之间的关联交易均为生产经营活动所必需，属于 正常业务往来。依据市场价格协商定价，遵循公平、合理的原则，根据实际情况 签订合同，不存在利用关联方关系损害上市公司利益的情形，不损害公司股东特 别是中小股东的利益。综上所述，我们一致同意将上述议案提交公司第九届董事 会第三十次会议进行审议，关联董事应回避表决。该议案尚需提交公司股东大会 审议。 二、关于控股股东及其他关联方占用公司资金、公司对外担保情况的议案 （一）关于公司 2024 年半年度控股股东及其他关联方占用资金情况 报告期内，公司与控股股东及其他关联方发生的资金往来 ...

Group 1: Company Strategy and Acquisition - The company is cautiously considering strategic transformation into the field of cell therapy, emphasizing the importance of thorough research and assessment before making significant changes [2] - Northeast Pharmaceutical plans to acquire 70% of the equity of Dingcheng Peptide Source, aligning with the vision of its actual controller in the cell therapy sector [3] Group 2: Research and Development Team - Dingcheng Peptide Source was established in 2014 and has a solid foundation in technology development, focusing on the discovery of TCR sequences since 2017 [3] - The R&D team consists of 121 members, with over 20 holding doctoral degrees and more than 50% having master's degrees [3] Group 3: Market Potential and Interest in Cell Therapy - There is a significant unmet medical need in tumor treatment, which cell therapy can address, making it an area of interest for the company [4] - The company views cell therapy as a strategic opportunity to gain a competitive advantage in the biopharmaceutical sector [4] Group 4: Product Development and Clinical Trials - Dingcheng Peptide Source is not in the first tier in terms of product approval or clinical stages, but its TCR-T product is expected to be the first in China to enter Phase I clinical trials targeting KRAS G12D [4] - The company has developed a robust TCR sequence library, which is crucial for future product development [5] Group 5: Cost Control and Efficiency - Northeast Pharmaceutical has implemented effective measures for cost control and efficiency improvement, focusing on detailed management to reduce waste and enhance productivity [5]

Group 1: Acquisition Background - Northeast Pharmaceutical Group Co., Ltd. is pursuing a transformation towards biopharmaceuticals and has been seeking suitable acquisition targets [2] - The company plans to acquire 70% of the shares of Beijing Dingcheng Peptide Source Biotechnology Co., Ltd. as conditions for the acquisition have matured [3] Group 2: Dingcheng Peptide Source's Technology and R&D Progress - Dingcheng Peptide Source, established in 2014, focuses on developing cell therapy products for solid tumors and is advancing two products into clinical trials [3] - One product targets KRAS-G12D TCR-T and has received implied approval for clinical trials from CDE, while another CAR-T product for glioblastoma received orphan drug designation from the FDA [3] - The company has developed multiple cell therapy products targeting gastric cancer, liver cancer, pancreatic cancer, and colorectal cancer, ready for IND application [3] Group 3: Clinical and Market Strategy - The KRAS mutation is prevalent in many solid tumors, with G12D being the most common in pancreatic cancer, colorectal cancer, small cell lung cancer, and ovarian cancer [5] - The company aims to prioritize high-expression indications for clinical trials and will consider expanding based on phase I results [5] Group 4: Financial and Operational Plans - The company will support Dingcheng Peptide Source's R&D without setting specific financial limits, aligning with market development progress [6] - Post-acquisition, the R&D team will have equity incentives to ensure stability and motivation [6] - The acquisition is a strategic move reflecting the management's confidence in transitioning to biopharmaceuticals [6]